Synonym
ACEA1011; ACEA-1011; ACEA 1011
IUPAC/Chemical Name
5-Chloro-1,4-dihydro-7-(trifluoromethyl)-2,3-quinoxalinedione
InChi Key
JDCKMCIQUXTYQI-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H4ClF3N2O2/c10-4-1-3(9(11,12)13)2-5-6(4)15-8(17)7(16)14-5/h1-2H,(H,14,16)(H,15,17)
SMILES Code
O=C1NC2=C(C(Cl)=CC(C(F)(F)F)=C2)NC1=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
264.59
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Balster RL, Mansbach RS, Shelton KL, Nicholson KL, Grech DM, Wiley JL, Li H, Weber E. Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol. 1995 Aug;6(5 And 6):577-589. PubMed PMID: 11224365.
2: Woodward RM, Huettner JE, Tran M, Guastella J, Keana JF, Weber E. Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist. J Pharmacol Exp Ther. 1995 Dec;275(3):1209-18. PubMed PMID: 8531083.
3: Lutfy K, Woodward RM, Keana JF, Weber E. Inhibition of clonic seizure-like excitatory effects induced by intrathecal morphine using two NMDA receptor antagonists: MK-801 and ACEA-1011. Eur J Pharmacol. 1994 Feb 11;252(3):261-6. PubMed PMID: 8162948.
4: Warner DS, Martin H, Ludwig P, McAllister A, Keana JF, Weber E. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab. 1995 Mar;15(2):188-96. PubMed PMID: 7860652.
5: Wilding TJ, Huettner JE. Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors. Mol Pharmacol. 1996 Mar;49(3):540-6. PubMed PMID: 8643094.
6: Lutfy K, Keana JF, Weber E. ACEA-1011, a novel NMDA receptor/glycine site antagonist, produces antinociception but not tolerance in the formalin test in mice. NIDA Res Monogr. 1995;147:220-33. PubMed PMID: 8742789.
7: Vaccarino AL, Marek P, Kest B, Weber E, Keana JF, Liebeskind JC. NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 1993 Jul 2;615(2):331-4. PubMed PMID: 8364741.
8: Lutfy K, Sadowski B, Marek P, Kwon IS, Keana JF, Weber E. Differential sensitivity of mice bred for stress-induced analgesia to morphine and ACEA-1011 in the formalin test. Pharmacol Biochem Behav. 1996 Jun;54(2):495-500. PubMed PMID: 8743614.
9: Matsumoto RR, Nguyen D, Truong DD. Strychnine-insensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder. Eur J Pharmacol. 1995 Mar 6;275(2):117-23. PubMed PMID: 7796845.
10: Pouw B, Nour M, Matsumoto RR. Effects of AMPA/kainate glutamate receptor antagonists on cocaine-induced convulsions and lethality in mice. Eur J Pharmacol. 1999 Dec 15;386(2-3):181-6. PubMed PMID: 10618468.
